🇪🇺 Tacrolimus targeted plain dose in European Union

EMA authorised Tacrolimus targeted plain dose on 23 April 2007

Marketing authorisation

EMA — authorised 23 April 2007

  • Application: EMEA/H/C/000712
  • Marketing authorisation holder: Astellas Pharma Europe BV
  • Local brand name: Advagraf
  • Indication: Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
  • Status: approved

Read official source →

Tacrolimus targeted plain dose in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Tacrolimus targeted plain dose approved in European Union?

Yes. EMA authorised it on 23 April 2007.

Who is the marketing authorisation holder for Tacrolimus targeted plain dose in European Union?

Astellas Pharma Europe BV holds the EU marketing authorisation.